SFM
BCRX icon

Soros Fund Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Soros Fund Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-59,700
Closed -$632K – 373
2014
Q1 		$632K Buy
+59,700
New +$636K 0.01% 258

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

Soros Fund Management's BCRX Position: Q2 2014 in Review

Soros Fund Management sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2014, closing a stake of 59,700 shares — an estimated $632K sold.

Soros Fund Management first reported a position in BCRX in Q1 2014 and held it in 1 quarter. The position peaked at $632K in Q1 2014. 103 funds tracked by Wall St. Rank hold BCRX as of Q2 2014.

  • Soros Fund Management reported no remaining BioCryst Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Soros Fund Management sold 59,700 BioCryst Pharmaceuticals shares in Q2 2014, an estimated $632K.
  • Soros Fund Management first reported a position in BioCryst Pharmaceuticals in Q1 2014 and held it in 1 quarter.
  • Soros Fund Management's BioCryst Pharmaceuticals position peaked at $632K in Q1 2014.
  • 103 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2014.

Based on Soros Fund Management's 13F filing for Q2 2014, filed 14 Aug 2014.